rituximab + cyclophosphamide + methotrexate + vincristine + prednisone

This appears to be a combination chemotherapy regimen used primarily for treating various types of lymphoma and certain autoimmune conditions. The regimen combines rituximab (a monoclonal antibody targeting CD20-positive B cells) with several chemotherapeutic agents and a corticosteroid. The search results indicate this combination is used in treating various B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and intravascular large B-cell lymphoma (IVLBCL). It's also used in some autoimmune conditions like ANCA-associated vasculitis. The regimen typically involves: - Rituximab: An anti-CD20 monoclonal antibody that targets B cells - Cyclophosphamide: An alkylating agent - Methotrexate: An antimetabolite - Vincristine: A vinca alkaloid that disrupts microtubules - Prednisone: A corticosteroid with anti-inflammatory and immunosuppressive properties This combination appears to be effective in inducing remission in various conditions, with studies showing high remission rates (94% in some studies). The treatment may also include intrathecal chemotherapy in some cases, particularly for CNS involvement. Side effects include those typical of chemotherapy regimens, and prophylaxis against infections like Pneumocystis pneumonia is typically recommended during treatment.